Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial-Reference-Cited by-同舟云学术

Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

Published:2021-09-07 Issue: Volume: Page:
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Claassens Daniel M. F.^ORCID,van Dorst Pim W. M.,Vos Gerrit J. A.,Bergmeijer Thomas O.,Hermanides Renicus S.,van ’t Hof Arnoud W. J.,van der Harst Pim,Barbato Emanuele,Morisco Carmine,Tjon Joe Gin Richard M.,Asselbergs Folkert W.,Mosterd Arend,Herrman Jean-Paul R.,Dewilde Willem J. M.,Postma Maarten J.,Deneer Vera H. M.,ten Berg Jurriën M.,Boersma Cornelis

Funder

ZonMw

Spartan Bioscience

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40256-021-00496-4.pdf

Reference31 articles.

1. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1082–115.

2. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.